# Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

> **NCT00044863** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 250 (actual)

## Conditions studied

- Colorectal Neoplasms
- Metastases, Neoplasm

## Interventions

- **BIOLOGICAL:** Erbitux (Cetuximab)

## Key facts

- **NCT ID:** NCT00044863
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2011-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044863, "Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00044863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*